Form 4: Eterna Therapeutics Director William Wexler Reports Stock Option Grant

Director William Wexler reports acquisition of stock options in Eterna Therapeutics.

Summary

• On February 7, 2025, William Wexler, a director of Eterna Therapeutics Inc., reported the acquisition of stock options.
• The stock option grants him the right to buy 124,533 shares of common stock at an exercise price of $0.34.
• The options vest over time, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in 24 equal monthly installments thereafter.
• The options expire on February 7, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a standard executive compensation practice that aligns management interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one-third after one year and the remainder over 24 months is a typical vesting arrangement.
• Comparable companies like Moderna or BioNTech also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates

Keywords

stock options, director, ERNA, Eterna Therapeutics, beneficial ownership, Form 4, Wexler, William Wexler